Exact Sciences has launched its Cancerguard test to screen for early stages of cancer. It is designed to detect more than 50 different types of malignancies such as those from pancreas, ovary, liver, lungs, esophagus and stomach. Notably, it excludes breast and prostate cancers. The test is designed for adults between the ages of 50 and 84 who have not received a cancer diagnosis within three years.
Cancerguard is a laboratory-developed test that costs $689. It will initially be available for physicians to order. Later, Exact Sciences plans to sell it to consumers through its own web portal. The company has partnered with Quest Diagnostics to collect blood specimens.
The company claims Cancerguard has a sensitivity of 68% in detecting the cancers mentioned above. It identified one third of Stage 1 or 2 cases. The false positive rate was less than 3%.
Exact Sciences is also offering care navigator services, plus up to $6,000 in reimbursements for some non-covered PET or CT scans that may be required to follow up and confirm a positive result.
Cancerguard is not FDA approved and is not covered by insurance.
Reference
Conor Hale, Fierce Biotech, Exact Sciences rolls out Canerguard multi-cancer blood test, Sep 11, 2025.
How to resolve AdBlock issue? 